ARTICLE | Emerging Company Profile

Hangzhou Highlightll: Twice the target, hold the tox

TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases

July 3, 2021 2:04 AM UTC

Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against the same targets to treat a broad range of autoimmune diseases. Both compounds would need to find a foothold in a crowded marketplace.

Hangzhou Highlightll Pharmaceutical Co. Ltd. announced Thursday that it raised more than RMB210 million ($30 million) across its series B and B+ rounds, with Hankang Capital leading the series B+...